167MO Association between ER, PR and HER2 levels and outcome under palbociclib (Pal) + aromatase inhibitors (AIs) as first-line therapy for ER+ HER2- metastatic breast cancer (MBC): An exploratory analysis of the PADA-1 trial
Titel:
167MO Association between ER, PR and HER2 levels and outcome under palbociclib (Pal) + aromatase inhibitors (AIs) as first-line therapy for ER+ HER2- metastatic breast cancer (MBC): An exploratory analysis of the PADA-1 trial
Auteur:
De La Motte Rouge, T. Frenel, J-S. Hardy-Bessard, A-C. Bachelot, T. Pistilli, B. Delaloge, S. Deiana, L. Del Piano, F. Genet, D. Gardner, M. Legouffe, E. Levache, C.B. Orfeuvre, H. Valmar, C. Venat, L. Zannetti, A. Le Scodan, R. Dalenc, F. Berger, D. Bidard, F.C.